Compare Eli Lilly And Co (LLY) vs Open Text Corporation (OTEX) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

OpenText (OTEX) trades at $23.33, up 0.26% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.3, EV/EBITDA of 6.71, and consistent earnings beats in recent quarters. Recent developments include a $105 million European AI investment and board appointments, while maintaining a 4.7% dividend yield.

OTEX presents value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include execution challenges in AI strategy and competitive software market pressures. Analyst consensus targets $29.75 (27.5% upside) with 42% buy ratings, though majority maintain hold stance awaiting clearer growth catalysts.